3//SEC Filing
Versant Venture Capital V, L.P. 3
Accession 0001104659-18-045567
CIK 0001658247other
Filed
Jul 16, 8:00 PM ET
Accepted
Jul 17, 7:40 PM ET
Size
22.8 KB
Accession
0001104659-18-045567
Insider Transaction Report
Form 3
Holdings
- (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (194,629 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (76,927 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (85,253 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (12,409 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (2,557,392 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (412,534 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (13,736 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (31,396 underlying)
Holdings
- (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (12,409 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (13,736 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (31,396 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (2,557,392 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (412,534 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (76,927 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (194,629 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (85,253 underlying)
Versant Venture Capital V, L.P.
10% Owner
Holdings
- (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (2,557,392 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (85,253 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (412,534 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (12,409 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (31,396 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (76,927 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (194,629 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (13,736 underlying)
Versant Affiliates Fund V, L.P.
10% Owner
Holdings
- (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (85,253 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (12,409 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (13,736 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (31,396 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (194,629 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (76,927 underlying) - (indirect: See footnotes)
Series A Preferred Stock
Exercise: $0.00→ Common Stock (2,557,392 underlying) - (indirect: See footnotes)
Series B Preferred Stock
Exercise: $0.00→ Common Stock (412,534 underlying)
Footnotes (7)
- [F1]Each of the 8,413,817, 253,091, 280,485 and 640,332 shares of Series A Preferred Stock held by Versant Venture Capital V, L.P. ("VVC V"), Versant Affiliates Fund V, L.P. ("VAF V"), Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") and Versant Venture Capital V (Canada) LP ("VVC CAN"), respectively, is convertible, at any time, at the holder's election, at a ratio of 3.29 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert at a ratio of 3.29 to one share of the Issuer's common stock. The Series A Preferred Stock has no expiration date.
- [F2]Each of the 1,357,240, 40,826, 45,192 and 103,293 shares of Series B Preferred Stock held by VVC V, VAF V, VOA and VVC CAN, respectively, is convertible, at any time, at the holder's election, at a ratio of 3.29 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert at a ratio of 3.29 to one share of the Issuer's common stock. The Series B Preferred Stock has no expiration date.
- [F3]These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein.
- [F4]These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VAF V; however, they each disclaim beneficial ownership of the shares held by VAF V, except to the extent of their pecuniary interests therein.
- [F5]These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VOA; however, they each disclaim beneficial ownership of the shares held by VOA, except to the extent of their pecuniary interests therein.
- [F6]These securities are held of record by VVC CAN. Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), LP ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein.
- [F7]This report on Form 3 is jointly filed by VVC V, VAF V, VOA and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Crinetics Pharmaceuticals, Inc.
CIK 0001658247
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001589097
Filing Metadata
- Form type
- 3
- Filed
- Jul 16, 8:00 PM ET
- Accepted
- Jul 17, 7:40 PM ET
- Size
- 22.8 KB